Literature DB >> 10839558

Diagnosis and treatment of atrophic vaginitis.

G A Bachmann1, N S Nevadunsky.   

Abstract

Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. Because the condition is attributable to estrogen deficiency, it may occur in premenopausal women who take antiestrogenic medications or who have medical or surgical conditions that result in decreased levels of estrogen. The thinned endometrium and increased vaginal pH level induced by estrogen deficiency predispose the vagina and urinary tract to infection and mechanical weakness. The earliest symptoms are decreased vaginal lubrication, followed by other vaginal and urinary symptoms that may be exacerbated by superimposed infection. Once other causes of symptoms have been eliminated, treatment usually depends on estrogen replacement. Estrogen replacement therapy may be provided systemically or locally, but the dosage and delivery method must be individualized. Vaginal moisturizers and lubricants, and participation in coitus may also be beneficial in the treatment of women with atrophic vaginitis.

Entities:  

Mesh:

Year:  2000        PMID: 10839558

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  44 in total

1.  Comparison of the Effects of Vaginal Royal Jelly and Vaginal Estrogen on Quality of Life, Sexual and Urinary Function in Postmenopausal Women.

Authors:  Fatemeh Seyyedi; Mahmoud Rafiean-Kopaei; Sepideh Miraj
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Evaluating vaginitis. The importance of patient factors.

Authors:  Lisa L Willett; Robert M Centor
Journal:  J Gen Intern Med       Date:  2005-09       Impact factor: 5.128

Review 3.  The etiology and management of recurrent urinary tract infections in postmenopausal women.

Authors:  Carrie Jung; Linda Brubaker
Journal:  Climacteric       Date:  2019-01-09       Impact factor: 3.005

4.  Vaginal estrogen use and chronic disease risk in the Nurses' Health Study.

Authors:  Shilpa N Bhupathiraju; Francine Grodstein; Meir J Stampfer; Walter C Willett; Carolyn J Crandall; Jan L Shifren; JoAnn E Manson
Journal:  Menopause       Date:  2018-12-17       Impact factor: 2.953

Review 5.  Assessment of vaginal atrophy: a review.

Authors:  M A Weber; J Limpens; J P W R Roovers
Journal:  Int Urogynecol J       Date:  2014-07-22       Impact factor: 2.894

Review 6.  Surface transperineal ultrasound and vaginal abnormalities: applications and strengths.

Authors:  Soha Talaat Hamed; Sahar Mahmoud Mansour
Journal:  Br J Radiol       Date:  2017-09-13       Impact factor: 3.039

7.  Pelvic floor dysfunction in female Sjögren's syndrome: an 8-year audit.

Authors:  Aaron K Budden; Nèvine I D Te West; Allan D Sturgess; Kate H Moore
Journal:  Int Urogynecol J       Date:  2016-03-10       Impact factor: 2.894

8.  Environmental exposure to di-2-ethylhexyl phthalate is associated with low interest in sexual activity in premenopausal women.

Authors:  Emily S Barrett; Lauren E Parlett; Christina Wang; Erma Z Drobnis; J Bruce Redmon; Shanna H Swan
Journal:  Horm Behav       Date:  2014-11-08       Impact factor: 3.587

9.  Using Wood's Light as a Diagnostic Tool for Vaginal Atrophy.

Authors:  Mustafa Ulubay; Mustafa Ozturk; Ulas Fidan; Ugur Keskin; Ibrahim Alanbay; Riza Karaca
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 10.  Missing documentation in breast cancer survivors: genitourinary syndrome of menopause.

Authors:  Elise D Cook; Elena I Iglehart; George Baum; Leslie L Schover; Lonzetta L Newman
Journal:  Menopause       Date:  2017-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.